Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Medicine Nov 29
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon* First-year learnings underline broader systemic issues in roll-out countries The digital pre
Medicine Nov 21

2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro Breezhaler , in the treatment of the majority of symptomatic COPD patients -   Bronchodilation regarded as th

Medicine Nov 18

No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks -   Innovative study design demonstrates switching between biosimi

Medicine Nov 16

STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus place

Medicine Nov 21

Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options -   Results of SUSTAIN will be presen

Medicine Nov 16

First results from global registrational trial of CAR T'therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia  Sub-group analyses from pivotal MONALEESA-2 trial of LEE011 (

Medicine Nov 15

Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril -   The


Medicine and Life Sciences